Novartis's smokers' cough treatment gets European nod
ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday the European Commission had approved its Seebri Breezhaler as a once-daily treatment for adult patients with chronic obstructive pulmonary disease, more commonly known as smoker's cough, in the European Union.
Trials showed that the treatment significantly improved lung function over the first four hours after morning dosing when compared to placebo, and that this benefit was sustained for 24 hours over a 52-week period, Novartis said.
The group said the treatment will be available to physicians and patients in some European Union markets by year end.
Deutsche Bank has estimated peak sales for Seebri Breezhaler at some $500 million.
(Reporting by Martin de Sa'Pinto)
- Thousands of Gaza civilians flee after Israeli warning |
- Russia threatens Ukraine after shell crosses border
- Three dead, two wounded in Pasadena, California shootings
- Teen survivor of Texas shootings says slain family members 'in much better place'
- Heavy fighting breaks out near Libya's Tripoli airport, seven dead
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video